Global Life Science Business Partnering (GLSBP) - February 2022

Highlights of February 2022

  1. Glenmark Pharmaceuticals enters into licensing agreement with AstraZeneca Colombia for the commercialization of AstraZeneca’s drug Pulmicort Respules.
  2. CEPI, THSTI, Panacea Biotec partner to develop Betacoronavirus vaccines.
  3. Binnopharm to acquire two anti-bacterial brands from Dr Reddy’s.
  4. Lupin enters pact with Medis for Lupin’s orphan drug NaMuscla (mexiletine).
  5. Dr Reddy's Laboratories entered into an exclusive sales and distribution agreement with Novartis India Limited (NIL) for the Voveran range, the Calcium range and Methergine.
  6. Intellia-ONK ink up to $920 Million pact for 5 CRISPR-edited cancer cell therapies
  7. CooperSurgical to acquire Cook Medical's IVF, OB-GYN businesses for $875 Million.
  8. Aurealis Therapeutics enters into $139 Million USD agreement with Xbiome.
  9. Recipharm acquires Arranta Bio and Vibalogics.
  10. Code Biotherapeutics inks collaboration with Takeda on rare diseases.
  11. Clinigen and Deciphera ink distribution deal for GIST drug.
  12. MaaT Pharma partners with Skyepharma on microbiome production.
  13. Collegium to acquire pain drug developer BioDelivery Sciences.
  14. Element Biosciences acquires Loop Genomics to add long-read tech to DNA sequencing platform.

Highlights at Aagami:

  1. Aagami signs contract extension with its San Francisco Bay area Biotechnology client.
  2. Aagami to attend BIO International Convention in June 2022.

INFOCUS: Select opportunities available at Aagami:

For Acquisition:

  1. Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package, IP etc.- for Next-generation biologics and substantial returns. Available at a very reasonable price.

For Partnering/Licensing/ Investment:

  1. US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications. Extended Series B note with discount on Series C available for a limited time. Contact us now.
  2. Seeking $7M Bridge to Series B (Over $5M fully committed) - Novel Evolution of Portable MRI and Robotics for Strokes and TBI. Total of $7.8M has been Raised so far.
  3. Series A - $25M Financing: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
  4. Licensing, Co-development - Oncology assets such as Docetaxel, Cabazitaxel and Bendamustine, with low cost and accelerated route to market approval. Negligible competition(2) for Bendamustine in the $600M US market.
  5. Seeking Investment/Strategic partnerships our Euronext listed French client’s ongoing Phase 2 injectable drug candidate (NFL-101) for smoking cessation. Dosing regimen: delivered subcutaneously, twice, one week apart.
  6. Available for licensing: Phase I asset for Moderate-Severe Pain; Fast Track designation; Clinical Study on-going.
  7. Available for licensing: Transdermal smart patch asset with Proprietary technology for Alzheimer’s Disease; IND filing in progress. Safer and non-irritable.
  8. Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system to deliver drugs, vaccines; better immune response than injection. A painless and efficient replacement to Syringes.
  9. Seeking $2.5M in Seed round – Natural and Soluble Melanin (100sX lower cost) with applications in Drugs, Biomedical, cosmetics, Aerospace, energy systems to name a few. Raised $650,000 till date from Indiebio Accelerator, SOSV and other VC funds. 40% commitment already received from existing investors.
×
Twitter